Here are five takeaways:
1. The grant money will help the company fund its new spine surgery device, which involves a titanium plate securing spinal vertebrae during healing following surgery.
2. ReVivo President and CEO, Gary Mittleman, said the money will specifically fund the device’s testing on animals.
3. The device has not secured FDA approval, yet.
4. ReVivo will still need $500,000 to $800,000 to fund FDA testing and invest in products.
5. Albany (N.Y.) Medical Center spine surgeon Darryl DiRisio, MD, and biomedical engineers, Eric Ledet and Glenn Sanders, founded ReVivo Medical.
More articles on devices:
Regenexx receives US patent for stem cell procedure: 4 points
Smith & Nephew to acquire Blue Belt Technologies: 6 key notes
OrthoGrid creates new total hip replacement guide for HipGrid line: 5 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
